| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Berylliosis | 76 | 2024 | 186 | 14.470 |
Why?
|
| Beryllium | 60 | 2024 | 153 | 9.750 |
Why?
|
| Sarcoidosis | 40 | 2025 | 159 | 9.360 |
Why?
|
| Sarcoidosis, Pulmonary | 25 | 2025 | 83 | 6.310 |
Why?
|
| Occupational Exposure | 38 | 2024 | 341 | 5.970 |
Why?
|
| Occupational Diseases | 8 | 2024 | 156 | 2.450 |
Why?
|
| Gastrointestinal Microbiome | 10 | 2025 | 697 | 2.430 |
Why?
|
| Bacteria | 12 | 2025 | 858 | 2.320 |
Why?
|
| HLA-DP beta-Chains | 14 | 2024 | 86 | 2.220 |
Why?
|
| Salmonella typhimurium | 7 | 2025 | 183 | 2.000 |
Why?
|
| Lung Diseases | 10 | 2022 | 767 | 1.770 |
Why?
|
| Chronic Disease | 49 | 2022 | 1793 | 1.770 |
Why?
|
| Microbiota | 8 | 2025 | 762 | 1.750 |
Why?
|
| Bronchoalveolar Lavage Fluid | 26 | 2024 | 652 | 1.550 |
Why?
|
| Polymorphism, Genetic | 13 | 2021 | 660 | 1.370 |
Why?
|
| Symbiosis | 4 | 2025 | 79 | 1.350 |
Why?
|
| Genetic Predisposition to Disease | 17 | 2024 | 2426 | 1.340 |
Why?
|
| Bacteria, Anaerobic | 3 | 2025 | 25 | 1.320 |
Why?
|
| Humans | 178 | 2025 | 137585 | 1.210 |
Why?
|
| Adrenal Cortex Hormones | 5 | 2020 | 565 | 1.210 |
Why?
|
| HLA-DP Antigens | 9 | 2011 | 33 | 1.140 |
Why?
|
| Lung | 32 | 2025 | 4060 | 1.100 |
Why?
|
| Lymphocytes | 13 | 2020 | 397 | 1.070 |
Why?
|
| CD4-Positive T-Lymphocytes | 19 | 2021 | 1091 | 1.060 |
Why?
|
| Biomarkers | 14 | 2024 | 4149 | 1.010 |
Why?
|
| Case-Control Studies | 25 | 2024 | 3556 | 1.000 |
Why?
|
| Middle Aged | 78 | 2025 | 33479 | 0.930 |
Why?
|
| Biotechnology | 1 | 2025 | 42 | 0.920 |
Why?
|
| Leukocytes, Mononuclear | 8 | 2023 | 558 | 0.910 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 5 | 2022 | 1040 | 0.900 |
Why?
|
| Clostridium Infections | 1 | 2025 | 73 | 0.880 |
Why?
|
| High-Throughput Screening Assays | 2 | 2023 | 158 | 0.880 |
Why?
|
| Proton Pump Inhibitors | 1 | 2025 | 109 | 0.870 |
Why?
|
| Tumor Necrosis Factor-alpha | 14 | 2021 | 1242 | 0.860 |
Why?
|
| Anti-Bacterial Agents | 9 | 2025 | 1809 | 0.860 |
Why?
|
| Granuloma | 7 | 2024 | 92 | 0.860 |
Why?
|
| Gastrointestinal Tract | 3 | 2014 | 195 | 0.840 |
Why?
|
| Male | 93 | 2025 | 67762 | 0.840 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2017 | 350 | 0.840 |
Why?
|
| Gene Expression Regulation | 6 | 2021 | 2607 | 0.820 |
Why?
|
| Alveolitis, Extrinsic Allergic | 6 | 2021 | 97 | 0.800 |
Why?
|
| Tomography, X-Ray Computed | 9 | 2025 | 2691 | 0.790 |
Why?
|
| Lipopolysaccharide Receptors | 3 | 2015 | 85 | 0.780 |
Why?
|
| Nicotine | 2 | 2021 | 334 | 0.780 |
Why?
|
| Skin Diseases | 2 | 2024 | 149 | 0.780 |
Why?
|
| Female | 90 | 2025 | 73304 | 0.780 |
Why?
|
| Feces | 6 | 2025 | 484 | 0.760 |
Why?
|
| Gene-Environment Interaction | 1 | 2023 | 192 | 0.750 |
Why?
|
| Bacterial Infections | 1 | 2024 | 250 | 0.740 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2025 | 186 | 0.730 |
Why?
|
| Environmental Exposure | 6 | 2022 | 579 | 0.730 |
Why?
|
| Lymphocyte Activation | 18 | 2014 | 1142 | 0.700 |
Why?
|
| Alleles | 11 | 2023 | 891 | 0.680 |
Why?
|
| Hypersensitivity | 6 | 2014 | 257 | 0.670 |
Why?
|
| Mesalamine | 2 | 2017 | 10 | 0.640 |
Why?
|
| Genotype | 15 | 2024 | 1916 | 0.640 |
Why?
|
| HLA Antigens | 3 | 2015 | 240 | 0.640 |
Why?
|
| Aged | 46 | 2024 | 23961 | 0.630 |
Why?
|
| Drug Interactions | 1 | 2021 | 410 | 0.630 |
Why?
|
| Biomedical Research | 4 | 2022 | 692 | 0.610 |
Why?
|
| Receptors, IgG | 2 | 2018 | 75 | 0.600 |
Why?
|
| Adult | 59 | 2024 | 37929 | 0.600 |
Why?
|
| Phenotype | 11 | 2023 | 3196 | 0.590 |
Why?
|
| Respiratory Hypersensitivity | 5 | 2012 | 69 | 0.590 |
Why?
|
| Ecosystem | 1 | 2023 | 596 | 0.580 |
Why?
|
| Disease Progression | 9 | 2024 | 2757 | 0.580 |
Why?
|
| Immunity, Cellular | 2 | 2017 | 268 | 0.570 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2018 | 184 | 0.550 |
Why?
|
| Cytokines | 8 | 2019 | 2085 | 0.540 |
Why?
|
| Military Personnel | 1 | 2024 | 544 | 0.530 |
Why?
|
| Dyspnea | 2 | 2021 | 254 | 0.530 |
Why?
|
| Cough | 1 | 2018 | 122 | 0.530 |
Why?
|
| Gene Expression Profiling | 3 | 2021 | 1774 | 0.500 |
Why?
|
| Cell Proliferation | 13 | 2018 | 2475 | 0.490 |
Why?
|
| Host-Pathogen Interactions | 5 | 2024 | 364 | 0.490 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 3 | 2022 | 67 | 0.490 |
Why?
|
| Proteins | 3 | 2020 | 1009 | 0.490 |
Why?
|
| DNA Methylation | 3 | 2024 | 643 | 0.490 |
Why?
|
| Macrophages, Alveolar | 4 | 2020 | 391 | 0.480 |
Why?
|
| Pulmonary Diffusing Capacity | 3 | 2024 | 75 | 0.470 |
Why?
|
| Bronchoalveolar Lavage | 6 | 2022 | 93 | 0.470 |
Why?
|
| Asthma | 3 | 2020 | 2295 | 0.460 |
Why?
|
| Respiratory Function Tests | 8 | 2024 | 600 | 0.460 |
Why?
|
| Granulocytes | 1 | 2014 | 80 | 0.460 |
Why?
|
| Hydrogenase | 1 | 2014 | 12 | 0.450 |
Why?
|
| Salmonella Infections, Animal | 1 | 2014 | 38 | 0.450 |
Why?
|
| Salmonella Infections | 4 | 2025 | 57 | 0.450 |
Why?
|
| Anaerobiosis | 2 | 2025 | 64 | 0.450 |
Why?
|
| Immunization | 4 | 2008 | 411 | 0.450 |
Why?
|
| Animals | 30 | 2025 | 36940 | 0.440 |
Why?
|
| Severity of Illness Index | 11 | 2024 | 2828 | 0.430 |
Why?
|
| Mycophenolic Acid | 1 | 2014 | 117 | 0.430 |
Why?
|
| Particle Size | 4 | 2014 | 394 | 0.430 |
Why?
|
| Radiography, Thoracic | 3 | 2024 | 167 | 0.420 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2014 | 283 | 0.420 |
Why?
|
| Immunity, Innate | 4 | 2022 | 828 | 0.410 |
Why?
|
| Models, Immunological | 3 | 2013 | 100 | 0.410 |
Why?
|
| Allergens | 4 | 2012 | 409 | 0.400 |
Why?
|
| Mice | 18 | 2025 | 17787 | 0.390 |
Why?
|
| Odds Ratio | 6 | 2020 | 1070 | 0.390 |
Why?
|
| Periodicals as Topic | 1 | 2015 | 211 | 0.380 |
Why?
|
| Escherichia coli | 4 | 2025 | 815 | 0.380 |
Why?
|
| Cardiomyopathies | 5 | 2020 | 350 | 0.380 |
Why?
|
| T-Lymphocytes | 4 | 2022 | 1996 | 0.380 |
Why?
|
| Dendritic Cells | 2 | 2014 | 483 | 0.370 |
Why?
|
| Air Pollutants, Occupational | 2 | 2010 | 40 | 0.370 |
Why?
|
| Colitis | 1 | 2014 | 266 | 0.370 |
Why?
|
| Mandibular Fractures | 2 | 2022 | 11 | 0.370 |
Why?
|
| Immunosuppressive Agents | 3 | 2024 | 890 | 0.370 |
Why?
|
| Glutamic Acid | 4 | 2007 | 246 | 0.360 |
Why?
|
| Risk Factors | 15 | 2024 | 10388 | 0.360 |
Why?
|
| Diagnosis, Differential | 6 | 2024 | 1483 | 0.350 |
Why?
|
| Medical Laboratory Personnel | 1 | 2010 | 7 | 0.340 |
Why?
|
| Mandibular Nerve | 2 | 2020 | 5 | 0.330 |
Why?
|
| Quality of Life | 8 | 2024 | 2892 | 0.330 |
Why?
|
| Endotoxins | 2 | 2010 | 220 | 0.330 |
Why?
|
| Pulmonary Emphysema | 2 | 2023 | 288 | 0.330 |
Why?
|
| Forced Expiratory Volume | 4 | 2018 | 531 | 0.330 |
Why?
|
| Transcriptome | 4 | 2024 | 971 | 0.320 |
Why?
|
| Vital Capacity | 4 | 2019 | 311 | 0.320 |
Why?
|
| Receptors, CCR5 | 1 | 2010 | 56 | 0.320 |
Why?
|
| Antibodies, Monoclonal | 5 | 2012 | 1430 | 0.320 |
Why?
|
| Th1 Cells | 3 | 2013 | 143 | 0.310 |
Why?
|
| Lung Diseases, Interstitial | 2 | 2020 | 638 | 0.300 |
Why?
|
| Systems Biology | 2 | 2021 | 67 | 0.300 |
Why?
|
| Interferon-gamma | 8 | 2021 | 789 | 0.290 |
Why?
|
| Smoking | 6 | 2021 | 1627 | 0.290 |
Why?
|
| HLA-DR Antigens | 4 | 2015 | 228 | 0.290 |
Why?
|
| Klebsiella pneumoniae | 2 | 2025 | 47 | 0.290 |
Why?
|
| Exosomes | 2 | 2021 | 103 | 0.290 |
Why?
|
| Aged, 80 and over | 15 | 2020 | 7635 | 0.280 |
Why?
|
| Glutathione | 3 | 2017 | 356 | 0.280 |
Why?
|
| Logistic Models | 7 | 2020 | 2074 | 0.280 |
Why?
|
| Administration, Inhalation | 2 | 2020 | 688 | 0.270 |
Why?
|
| Proteomics | 6 | 2025 | 1111 | 0.270 |
Why?
|
| RNA | 3 | 2023 | 921 | 0.270 |
Why?
|
| United States | 13 | 2022 | 14841 | 0.270 |
Why?
|
| Pulmonary Fibrosis | 2 | 2020 | 402 | 0.270 |
Why?
|
| Bacterial Proteins | 3 | 2025 | 879 | 0.260 |
Why?
|
| Retrospective Studies | 10 | 2024 | 15657 | 0.260 |
Why?
|
| Lipopolysaccharides | 4 | 2025 | 886 | 0.250 |
Why?
|
| Mice, Inbred C57BL | 7 | 2025 | 5757 | 0.250 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2022 | 3566 | 0.250 |
Why?
|
| Reactive Oxygen Species | 3 | 2025 | 622 | 0.250 |
Why?
|
| Bronchoscopy | 5 | 2021 | 223 | 0.250 |
Why?
|
| Epitopes, T-Lymphocyte | 3 | 2021 | 181 | 0.250 |
Why?
|
| Bacteroides | 2 | 2025 | 21 | 0.240 |
Why?
|
| Spirometry | 2 | 2024 | 281 | 0.240 |
Why?
|
| Gammaproteobacteria | 1 | 2025 | 13 | 0.240 |
Why?
|
| Omeprazole | 1 | 2025 | 7 | 0.240 |
Why?
|
| Cause of Death | 2 | 2019 | 434 | 0.240 |
Why?
|
| Bioreactors | 1 | 2025 | 42 | 0.230 |
Why?
|
| T-Lymphocyte Subsets | 7 | 2013 | 417 | 0.230 |
Why?
|
| Mortality | 2 | 2019 | 362 | 0.230 |
Why?
|
| Cohort Studies | 4 | 2020 | 5742 | 0.230 |
Why?
|
| Intestines | 3 | 2025 | 357 | 0.230 |
Why?
|
| Membrane Glycoproteins | 1 | 2007 | 500 | 0.230 |
Why?
|
| Spiro Compounds | 1 | 2024 | 14 | 0.220 |
Why?
|
| Biopsy | 5 | 2020 | 1129 | 0.220 |
Why?
|
| Occupational Health | 2 | 2020 | 200 | 0.220 |
Why?
|
| Disease Models, Animal | 5 | 2021 | 4295 | 0.220 |
Why?
|
| Genome-Wide Association Study | 5 | 2024 | 1431 | 0.220 |
Why?
|
| Genetic Variation | 3 | 2023 | 991 | 0.220 |
Why?
|
| Ketones | 1 | 2024 | 49 | 0.220 |
Why?
|
| Central Nervous System Diseases | 2 | 2021 | 69 | 0.210 |
Why?
|
| Chemokine CX3CL1 | 1 | 2023 | 24 | 0.210 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2025 | 560 | 0.210 |
Why?
|
| Peritonitis | 1 | 2024 | 84 | 0.210 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2025 | 539 | 0.210 |
Why?
|
| Neopterin | 1 | 2003 | 12 | 0.210 |
Why?
|
| Escherichia coli Proteins | 1 | 2025 | 200 | 0.210 |
Why?
|
| Fluorocarbons | 1 | 2025 | 117 | 0.210 |
Why?
|
| Spirulina | 1 | 2023 | 4 | 0.200 |
Why?
|
| Cysteine Proteases | 1 | 2023 | 7 | 0.200 |
Why?
|
| Metagenomics | 2 | 2023 | 169 | 0.200 |
Why?
|
| Environmental Pollutants | 1 | 2025 | 159 | 0.200 |
Why?
|
| Genetic Association Studies | 2 | 2023 | 377 | 0.200 |
Why?
|
| Mandible | 2 | 2020 | 78 | 0.200 |
Why?
|
| Somatomedins | 1 | 2022 | 27 | 0.200 |
Why?
|
| Aerosols | 2 | 2020 | 176 | 0.200 |
Why?
|
| Double-Blind Method | 3 | 2017 | 1993 | 0.190 |
Why?
|
| Inhalation Exposure | 3 | 2020 | 105 | 0.190 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2003 | 367 | 0.190 |
Why?
|
| Stress, Physiological | 1 | 2025 | 443 | 0.190 |
Why?
|
| Dicumarol | 1 | 2021 | 3 | 0.190 |
Why?
|
| Cell Membrane | 1 | 2025 | 738 | 0.190 |
Why?
|
| Tetracyclines | 1 | 2021 | 11 | 0.190 |
Why?
|
| Duloxetine Hydrochloride | 1 | 2021 | 11 | 0.190 |
Why?
|
| Erythromycin | 1 | 2021 | 25 | 0.180 |
Why?
|
| Aspergillus nidulans | 1 | 2021 | 6 | 0.180 |
Why?
|
| Germ-Free Life | 1 | 2021 | 34 | 0.180 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 2 | 2022 | 104 | 0.180 |
Why?
|
| Sputum | 2 | 2014 | 311 | 0.180 |
Why?
|
| Dust | 1 | 2022 | 100 | 0.180 |
Why?
|
| Immunologic Tests | 1 | 2001 | 16 | 0.180 |
Why?
|
| Chemokine CCL3 | 1 | 2021 | 16 | 0.180 |
Why?
|
| Chemokine CCL4 | 1 | 2021 | 23 | 0.180 |
Why?
|
| Nuclear Weapons | 2 | 2011 | 5 | 0.180 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2024 | 234 | 0.180 |
Why?
|
| Macrolides | 1 | 2021 | 65 | 0.180 |
Why?
|
| Hydrogen Sulfide | 1 | 2001 | 44 | 0.180 |
Why?
|
| T-Lymphocytes, Regulatory | 4 | 2021 | 385 | 0.170 |
Why?
|
| Silicon Dioxide | 1 | 2022 | 115 | 0.170 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 21 | 0.170 |
Why?
|
| Societies | 1 | 2020 | 39 | 0.170 |
Why?
|
| Circulating MicroRNA | 1 | 2021 | 24 | 0.170 |
Why?
|
| Maximum Allowable Concentration | 1 | 2020 | 16 | 0.170 |
Why?
|
| Immunoglobulin G | 4 | 2022 | 893 | 0.170 |
Why?
|
| Arthroplasty, Replacement | 1 | 2021 | 45 | 0.170 |
Why?
|
| Cluster Analysis | 1 | 2022 | 499 | 0.170 |
Why?
|
| Salmo salar | 1 | 2020 | 1 | 0.170 |
Why?
|
| Aquaculture | 1 | 2020 | 4 | 0.170 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2025 | 752 | 0.170 |
Why?
|
| Smoke | 1 | 2021 | 141 | 0.170 |
Why?
|
| Personal Protective Equipment | 1 | 2020 | 52 | 0.160 |
Why?
|
| Interleukin-4 | 1 | 2001 | 216 | 0.160 |
Why?
|
| Unemployment | 1 | 2020 | 43 | 0.160 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2020 | 75 | 0.160 |
Why?
|
| Communicable Diseases | 1 | 2022 | 159 | 0.160 |
Why?
|
| Lingual Nerve | 1 | 2019 | 1 | 0.160 |
Why?
|
| Longitudinal Studies | 5 | 2017 | 2844 | 0.160 |
Why?
|
| Extracellular Vesicles | 1 | 2022 | 146 | 0.160 |
Why?
|
| Sensitivity and Specificity | 5 | 2013 | 1946 | 0.160 |
Why?
|
| Masks | 1 | 2020 | 63 | 0.160 |
Why?
|
| Macrophages | 3 | 2021 | 1547 | 0.160 |
Why?
|
| Microbial Interactions | 1 | 2019 | 18 | 0.160 |
Why?
|
| Retinal Artery | 1 | 2019 | 17 | 0.160 |
Why?
|
| Electrocardiography | 2 | 2020 | 629 | 0.160 |
Why?
|
| Iron | 1 | 2021 | 313 | 0.160 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 1 | 2019 | 82 | 0.150 |
Why?
|
| Inflammation Mediators | 3 | 2012 | 513 | 0.150 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 1999 | 52 | 0.150 |
Why?
|
| Eating | 1 | 2021 | 380 | 0.150 |
Why?
|
| Propensity Score | 1 | 2020 | 294 | 0.150 |
Why?
|
| Pneumoconiosis | 1 | 2019 | 19 | 0.150 |
Why?
|
| Income | 1 | 2020 | 202 | 0.150 |
Why?
|
| Biological Evolution | 2 | 2013 | 474 | 0.150 |
Why?
|
| Immunologic Memory | 4 | 2013 | 353 | 0.150 |
Why?
|
| Kidney Diseases | 2 | 2020 | 408 | 0.150 |
Why?
|
| Antioxidants | 2 | 2016 | 584 | 0.150 |
Why?
|
| Regression Analysis | 3 | 2019 | 1024 | 0.150 |
Why?
|
| Virulence Factors | 3 | 2014 | 167 | 0.150 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2020 | 157 | 0.150 |
Why?
|
| Residual Volume | 1 | 2018 | 6 | 0.140 |
Why?
|
| Algorithms | 2 | 2020 | 1704 | 0.140 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2024 | 2189 | 0.140 |
Why?
|
| Chemokines | 2 | 2019 | 228 | 0.140 |
Why?
|
| Gene Expression | 2 | 2021 | 1502 | 0.140 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2016 | 346 | 0.140 |
Why?
|
| Immunologic Factors | 1 | 2020 | 236 | 0.140 |
Why?
|
| Metagenome | 2 | 2022 | 147 | 0.140 |
Why?
|
| Cost of Illness | 1 | 2020 | 308 | 0.140 |
Why?
|
| Cell Division | 7 | 2025 | 794 | 0.140 |
Why?
|
| In Vitro Techniques | 2 | 2018 | 1092 | 0.140 |
Why?
|
| Microbial Viability | 1 | 2018 | 91 | 0.140 |
Why?
|
| Dietary Fats | 1 | 2019 | 304 | 0.140 |
Why?
|
| September 11 Terrorist Attacks | 1 | 2017 | 32 | 0.140 |
Why?
|
| Cellular Senescence | 1 | 2019 | 189 | 0.140 |
Why?
|
| Dental Technicians | 2 | 2014 | 2 | 0.140 |
Why?
|
| Reproducibility of Results | 4 | 2021 | 3284 | 0.140 |
Why?
|
| Monocytes | 2 | 2023 | 563 | 0.140 |
Why?
|
| Betacoronavirus | 1 | 2020 | 270 | 0.140 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2018 | 97 | 0.130 |
Why?
|
| Arthritis, Juvenile | 1 | 2017 | 56 | 0.130 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 322 | 0.130 |
Why?
|
| Pilot Projects | 2 | 2020 | 1710 | 0.130 |
Why?
|
| Firefighters | 1 | 2017 | 43 | 0.130 |
Why?
|
| Ventricular Function, Right | 1 | 2019 | 285 | 0.130 |
Why?
|
| Liver Diseases | 1 | 2020 | 315 | 0.130 |
Why?
|
| HLA-DQ Antigens | 2 | 2010 | 181 | 0.130 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2019 | 333 | 0.130 |
Why?
|
| Biological Products | 1 | 2020 | 216 | 0.130 |
Why?
|
| Promoter Regions, Genetic | 3 | 2019 | 1250 | 0.130 |
Why?
|
| Congresses as Topic | 1 | 2018 | 233 | 0.130 |
Why?
|
| Air Pollutants | 1 | 2001 | 430 | 0.130 |
Why?
|
| Positron-Emission Tomography | 2 | 2020 | 294 | 0.130 |
Why?
|
| Banking, Personal | 1 | 2016 | 2 | 0.130 |
Why?
|
| Genome, Human | 1 | 2019 | 425 | 0.130 |
Why?
|
| Lung Injury | 1 | 2019 | 219 | 0.130 |
Why?
|
| Global Health | 2 | 2018 | 386 | 0.130 |
Why?
|
| Predictive Value of Tests | 5 | 2019 | 2031 | 0.120 |
Why?
|
| Disease Management | 1 | 2020 | 628 | 0.120 |
Why?
|
| Deoxyguanosine | 1 | 2016 | 25 | 0.120 |
Why?
|
| Action Potentials | 1 | 2019 | 493 | 0.120 |
Why?
|
| Death Certificates | 1 | 2016 | 30 | 0.120 |
Why?
|
| Health Care Sector | 1 | 2016 | 25 | 0.120 |
Why?
|
| Antipsychotic Agents | 1 | 2018 | 194 | 0.120 |
Why?
|
| Young Adult | 9 | 2022 | 13209 | 0.120 |
Why?
|
| Poisson Distribution | 1 | 2016 | 75 | 0.120 |
Why?
|
| Ventricular Function, Left | 1 | 2019 | 534 | 0.120 |
Why?
|
| Decision Support Techniques | 1 | 2020 | 421 | 0.120 |
Why?
|
| HLA-DRB1 Chains | 3 | 2023 | 112 | 0.120 |
Why?
|
| Adaptive Immunity | 2 | 2019 | 165 | 0.120 |
Why?
|
| Exercise Tolerance | 1 | 2018 | 279 | 0.120 |
Why?
|
| MicroRNAs | 2 | 2024 | 692 | 0.120 |
Why?
|
| Diet | 2 | 2021 | 1278 | 0.120 |
Why?
|
| Transcription, Genetic | 2 | 2016 | 1457 | 0.120 |
Why?
|
| Heart Rate | 1 | 2019 | 822 | 0.120 |
Why?
|
| Adolescent | 10 | 2020 | 21513 | 0.120 |
Why?
|
| Mass Screening | 2 | 2018 | 1287 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 373 | 0.120 |
Why?
|
| Pandemics | 2 | 2022 | 1639 | 0.120 |
Why?
|
| Drug Administration Schedule | 2 | 2014 | 786 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 364 | 0.120 |
Why?
|
| Commerce | 1 | 2016 | 82 | 0.120 |
Why?
|
| Streptomycin | 1 | 2014 | 18 | 0.120 |
Why?
|
| Acetylcysteine | 1 | 2016 | 145 | 0.120 |
Why?
|
| Cecum | 1 | 2014 | 33 | 0.120 |
Why?
|
| International Classification of Diseases | 1 | 2016 | 135 | 0.120 |
Why?
|
| Patch Tests | 3 | 2021 | 57 | 0.110 |
Why?
|
| Metals | 1 | 2016 | 136 | 0.110 |
Why?
|
| Drug Evaluation | 1 | 2014 | 84 | 0.110 |
Why?
|
| Enterococcus faecium | 2 | 2025 | 20 | 0.110 |
Why?
|
| Toll-Like Receptor 4 | 2 | 2025 | 273 | 0.110 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 2014 | 55 | 0.110 |
Why?
|
| Glucocorticoids | 2 | 2020 | 594 | 0.110 |
Why?
|
| Sex Factors | 2 | 2021 | 2071 | 0.110 |
Why?
|
| Cells, Cultured | 7 | 2013 | 4193 | 0.110 |
Why?
|
| Environmental Monitoring | 2 | 2014 | 370 | 0.110 |
Why?
|
| Heart Diseases | 1 | 2017 | 346 | 0.110 |
Why?
|
| Metallurgy | 1 | 2014 | 8 | 0.110 |
Why?
|
| CD40 Antigens | 1 | 2014 | 89 | 0.110 |
Why?
|
| Haplotypes | 4 | 2010 | 494 | 0.110 |
Why?
|
| Israel | 1 | 2014 | 56 | 0.110 |
Why?
|
| Apoptosis | 4 | 2005 | 2553 | 0.110 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2016 | 767 | 0.110 |
Why?
|
| Colorado | 4 | 2020 | 4565 | 0.110 |
Why?
|
| Population Surveillance | 3 | 2009 | 482 | 0.110 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 2 | 2014 | 336 | 0.110 |
Why?
|
| B-Lymphocytes | 1 | 2019 | 847 | 0.100 |
Why?
|
| Prednisone | 1 | 2014 | 240 | 0.100 |
Why?
|
| Teaching | 1 | 2016 | 224 | 0.100 |
Why?
|
| Genetic Markers | 3 | 2021 | 344 | 0.100 |
Why?
|
| Oxidative Stress | 3 | 2016 | 1317 | 0.100 |
Why?
|
| Myocardial Infarction | 1 | 2021 | 1046 | 0.100 |
Why?
|
| Occupational Health Services | 1 | 2013 | 32 | 0.100 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2025 | 361 | 0.100 |
Why?
|
| Imidazoles | 1 | 2014 | 238 | 0.100 |
Why?
|
| Models, Theoretical | 2 | 2014 | 578 | 0.100 |
Why?
|
| Liver | 1 | 2021 | 1943 | 0.100 |
Why?
|
| Pulmonary Gas Exchange | 2 | 2004 | 121 | 0.100 |
Why?
|
| CTLA-4 Antigen | 1 | 2013 | 99 | 0.100 |
Why?
|
| Nickel | 1 | 2013 | 62 | 0.100 |
Why?
|
| Enzyme Activation | 1 | 2014 | 810 | 0.100 |
Why?
|
| Phagocytosis | 1 | 2015 | 380 | 0.100 |
Why?
|
| Membrane Proteins | 2 | 2020 | 1164 | 0.100 |
Why?
|
| NF-kappa B | 2 | 2014 | 691 | 0.100 |
Why?
|
| MAP Kinase Signaling System | 1 | 2014 | 320 | 0.100 |
Why?
|
| o-Phthalaldehyde | 1 | 2012 | 3 | 0.100 |
Why?
|
| Radiopharmaceuticals | 1 | 2013 | 178 | 0.100 |
Why?
|
| Static Electricity | 1 | 2012 | 118 | 0.100 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2013 | 135 | 0.100 |
Why?
|
| Dermatitis, Allergic Contact | 1 | 2013 | 73 | 0.100 |
Why?
|
| Linkage Disequilibrium | 2 | 2010 | 268 | 0.090 |
Why?
|
| Ceftriaxone | 1 | 2012 | 21 | 0.090 |
Why?
|
| Industry | 2 | 2011 | 68 | 0.090 |
Why?
|
| Infliximab | 1 | 2012 | 111 | 0.090 |
Why?
|
| Ciprofloxacin | 1 | 2012 | 29 | 0.090 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2019 | 657 | 0.090 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2012 | 164 | 0.090 |
Why?
|
| Risk Assessment | 4 | 2020 | 3457 | 0.090 |
Why?
|
| Treatment Outcome | 5 | 2024 | 10811 | 0.090 |
Why?
|
| Epidermis | 1 | 2012 | 157 | 0.090 |
Why?
|
| Drug Therapy, Combination | 1 | 2014 | 1066 | 0.090 |
Why?
|
| Amino Acid Substitution | 1 | 2012 | 307 | 0.090 |
Why?
|
| Metabolomics | 3 | 2023 | 678 | 0.090 |
Why?
|
| Mutation | 3 | 2025 | 3958 | 0.090 |
Why?
|
| Psoriasis | 1 | 2012 | 102 | 0.090 |
Why?
|
| Surveys and Questionnaires | 4 | 2021 | 5778 | 0.090 |
Why?
|
| DNA | 3 | 2016 | 1459 | 0.090 |
Why?
|
| Receptors, Cell Surface | 3 | 2020 | 385 | 0.090 |
Why?
|
| Gene Frequency | 3 | 2010 | 521 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 2 | 2011 | 1062 | 0.090 |
Why?
|
| Diarrhea | 1 | 2012 | 184 | 0.090 |
Why?
|
| Pyridines | 1 | 2014 | 506 | 0.090 |
Why?
|
| Forced Expiratory Flow Rates | 1 | 2010 | 14 | 0.090 |
Why?
|
| fas Receptor | 2 | 2008 | 95 | 0.090 |
Why?
|
| Endocytosis | 1 | 1991 | 172 | 0.080 |
Why?
|
| Interleukins | 1 | 2012 | 250 | 0.080 |
Why?
|
| Trigeminal Nerve Injuries | 2 | 2020 | 3 | 0.080 |
Why?
|
| Genes, MHC Class II | 1 | 2010 | 74 | 0.080 |
Why?
|
| Occupations | 2 | 2019 | 49 | 0.080 |
Why?
|
| Hospitalization | 1 | 2020 | 2199 | 0.080 |
Why?
|
| Phosphorylation | 1 | 2014 | 1759 | 0.080 |
Why?
|
| Sulfasalazine | 1 | 2009 | 23 | 0.080 |
Why?
|
| Up-Regulation | 3 | 2008 | 843 | 0.080 |
Why?
|
| Diagnostic Errors | 1 | 2011 | 170 | 0.080 |
Why?
|
| Prognosis | 3 | 2021 | 4030 | 0.080 |
Why?
|
| Antigens | 2 | 2021 | 357 | 0.080 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 7 | 1 | 2009 | 28 | 0.080 |
Why?
|
| Exercise Test | 2 | 2003 | 625 | 0.080 |
Why?
|
| RNA, Ribosomal, 16S | 2 | 2023 | 549 | 0.080 |
Why?
|
| Virulence | 2 | 2025 | 267 | 0.080 |
Why?
|
| Uveitis | 1 | 2010 | 136 | 0.080 |
Why?
|
| Homozygote | 2 | 2007 | 203 | 0.080 |
Why?
|
| Research Design | 1 | 2015 | 1139 | 0.080 |
Why?
|
| Animals, Laboratory | 1 | 2008 | 18 | 0.070 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2008 | 26 | 0.070 |
Why?
|
| Multivariate Analysis | 3 | 2020 | 1509 | 0.070 |
Why?
|
| Inflammation | 5 | 2023 | 2837 | 0.070 |
Why?
|
| HLA-D Antigens | 1 | 2008 | 34 | 0.070 |
Why?
|
| Butyrophilins | 1 | 2007 | 6 | 0.070 |
Why?
|
| Time Factors | 3 | 2019 | 6828 | 0.070 |
Why?
|
| Proto-Oncogene Proteins | 1 | 1991 | 648 | 0.070 |
Why?
|
| Eye Diseases | 2 | 2020 | 87 | 0.070 |
Why?
|
| Linear Models | 2 | 2021 | 849 | 0.070 |
Why?
|
| Antigen Presentation | 2 | 2005 | 218 | 0.070 |
Why?
|
| CD57 Antigens | 1 | 2007 | 17 | 0.070 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2008 | 188 | 0.070 |
Why?
|
| Fatal Outcome | 1 | 2008 | 303 | 0.070 |
Why?
|
| Prevalence | 2 | 2011 | 2734 | 0.070 |
Why?
|
| Antigens, CD | 2 | 2008 | 521 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2019 | 3715 | 0.070 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2007 | 165 | 0.060 |
Why?
|
| Glutamate-Cysteine Ligase | 1 | 2006 | 20 | 0.060 |
Why?
|
| Total Lung Capacity | 1 | 2006 | 33 | 0.060 |
Why?
|
| Flow Cytometry | 3 | 2023 | 1178 | 0.060 |
Why?
|
| Protein Binding | 1 | 2012 | 2224 | 0.060 |
Why?
|
| B7-2 Antigen | 2 | 2017 | 27 | 0.060 |
Why?
|
| Netherlands | 2 | 2019 | 88 | 0.060 |
Why?
|
| Cell Separation | 2 | 2023 | 318 | 0.060 |
Why?
|
| Cell Line | 5 | 2013 | 2847 | 0.060 |
Why?
|
| Chemical Industry | 1 | 2005 | 12 | 0.060 |
Why?
|
| Mice, Transgenic | 2 | 2021 | 2167 | 0.060 |
Why?
|
| Cytoskeletal Proteins | 1 | 2025 | 158 | 0.060 |
Why?
|
| Nuclear Warfare | 1 | 2004 | 10 | 0.060 |
Why?
|
| Protein Structure, Secondary | 1 | 2005 | 374 | 0.060 |
Why?
|
| Biomarkers, Tumor | 1 | 1991 | 1276 | 0.060 |
Why?
|
| Ferritins | 1 | 2004 | 64 | 0.050 |
Why?
|
| Endotoxemia | 1 | 2025 | 86 | 0.050 |
Why?
|
| Anastomotic Leak | 1 | 2024 | 41 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2017 | 5131 | 0.050 |
Why?
|
| HLA-DRB3 Chains | 1 | 2003 | 2 | 0.050 |
Why?
|
| HLA-DRB5 Chains | 1 | 2003 | 2 | 0.050 |
Why?
|
| Molecular Docking Simulation | 1 | 2024 | 114 | 0.050 |
Why?
|
| HLA-DRB4 Chains | 1 | 2003 | 6 | 0.050 |
Why?
|
| Moths | 1 | 2024 | 45 | 0.050 |
Why?
|
| Sutures | 1 | 2024 | 58 | 0.050 |
Why?
|
| CX3C Chemokine Receptor 1 | 1 | 2023 | 19 | 0.050 |
Why?
|
| Genomics | 2 | 2022 | 795 | 0.050 |
Why?
|
| Laparotomy | 1 | 2024 | 109 | 0.050 |
Why?
|
| HLA-DR alpha-Chains | 1 | 2023 | 4 | 0.050 |
Why?
|
| HLA-DQ beta-Chains | 1 | 2003 | 63 | 0.050 |
Why?
|
| Larva | 1 | 2024 | 226 | 0.050 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2004 | 172 | 0.050 |
Why?
|
| Phycobilins | 1 | 2023 | 4 | 0.050 |
Why?
|
| Phycocyanin | 1 | 2023 | 4 | 0.050 |
Why?
|
| Decision Making | 1 | 2010 | 900 | 0.050 |
Why?
|
| Endothelium | 1 | 2023 | 123 | 0.050 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2025 | 328 | 0.050 |
Why?
|
| Societies, Medical | 2 | 2020 | 820 | 0.050 |
Why?
|
| Reference Standards | 1 | 2023 | 186 | 0.050 |
Why?
|
| Cobalt | 1 | 2002 | 52 | 0.050 |
Why?
|
| RNA, Messenger | 3 | 2024 | 2833 | 0.050 |
Why?
|
| Aluminum | 1 | 2002 | 42 | 0.050 |
Why?
|
| Thorax | 1 | 2022 | 50 | 0.050 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2025 | 352 | 0.050 |
Why?
|
| Granuloma, Respiratory Tract | 1 | 2002 | 12 | 0.050 |
Why?
|
| alpha 1-Antitrypsin | 1 | 2023 | 108 | 0.050 |
Why?
|
| Immunity, Active | 1 | 2002 | 10 | 0.050 |
Why?
|
| Iron Metabolism Disorders | 1 | 2021 | 5 | 0.050 |
Why?
|
| Myosins | 1 | 2022 | 135 | 0.050 |
Why?
|
| Whole Body Imaging | 1 | 2021 | 25 | 0.050 |
Why?
|
| Potassium, Dietary | 1 | 2021 | 12 | 0.050 |
Why?
|
| DNA Probes, HLA | 1 | 2001 | 1 | 0.050 |
Why?
|
| Cell Communication | 1 | 2023 | 315 | 0.050 |
Why?
|
| Diet Surveys | 1 | 2021 | 95 | 0.050 |
Why?
|
| Dietary Fiber | 1 | 2021 | 54 | 0.050 |
Why?
|
| Bronchiolitis | 1 | 2002 | 80 | 0.050 |
Why?
|
| Administration, Oral | 2 | 2016 | 816 | 0.050 |
Why?
|
| Cells | 1 | 2021 | 25 | 0.050 |
Why?
|
| Epitopes | 1 | 2003 | 479 | 0.050 |
Why?
|
| Antigens, Fungal | 1 | 2021 | 28 | 0.050 |
Why?
|
| Eosinophil Cationic Protein | 1 | 2021 | 10 | 0.050 |
Why?
|
| Enzyme-Linked Immunospot Assay | 2 | 2011 | 36 | 0.050 |
Why?
|
| Ligands | 1 | 2023 | 664 | 0.040 |
Why?
|
| HLA-DR3 Antigen | 1 | 2021 | 80 | 0.040 |
Why?
|
| Mining | 1 | 2001 | 22 | 0.040 |
Why?
|
| Oxygen Consumption | 1 | 2004 | 696 | 0.040 |
Why?
|
| CD28 Antigens | 2 | 2013 | 53 | 0.040 |
Why?
|
| CD55 Antigens | 1 | 2021 | 30 | 0.040 |
Why?
|
| Hybridomas | 1 | 2021 | 237 | 0.040 |
Why?
|
| Chemokine CXCL9 | 1 | 2021 | 27 | 0.040 |
Why?
|
| Minimal Clinically Important Difference | 1 | 2021 | 16 | 0.040 |
Why?
|
| Immunoglobulin M | 1 | 2022 | 289 | 0.040 |
Why?
|
| Click Chemistry | 1 | 2021 | 49 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2021 | 117 | 0.040 |
Why?
|
| Fungal Proteins | 1 | 2021 | 123 | 0.040 |
Why?
|
| Bone Cements | 1 | 2021 | 43 | 0.040 |
Why?
|
| Chi-Square Distribution | 3 | 2011 | 530 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 852 | 0.040 |
Why?
|
| Radiography | 1 | 2003 | 822 | 0.040 |
Why?
|
| Oxygen | 2 | 2022 | 931 | 0.040 |
Why?
|
| CD11c Antigen | 1 | 2020 | 41 | 0.040 |
Why?
|
| Biomedical Engineering | 1 | 2020 | 27 | 0.040 |
Why?
|
| Th17 Cells | 1 | 2021 | 108 | 0.040 |
Why?
|
| Serologic Tests | 1 | 2020 | 54 | 0.040 |
Why?
|
| Pharmaceutical Preparations | 1 | 2022 | 179 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2021 | 310 | 0.040 |
Why?
|
| Fatigue Syndrome, Chronic | 1 | 2020 | 17 | 0.040 |
Why?
|
| Lymphadenopathy | 1 | 2020 | 10 | 0.040 |
Why?
|
| Mediastinum | 1 | 2020 | 23 | 0.040 |
Why?
|
| Textiles | 1 | 2020 | 22 | 0.040 |
Why?
|
| Hypercalcemia | 1 | 2020 | 19 | 0.040 |
Why?
|
| Medical History Taking | 1 | 2020 | 117 | 0.040 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 82 | 0.040 |
Why?
|
| Self-Help Devices | 1 | 2020 | 20 | 0.040 |
Why?
|
| Receptors, Fc | 1 | 2020 | 53 | 0.040 |
Why?
|
| Intersectoral Collaboration | 1 | 2020 | 60 | 0.040 |
Why?
|
| Stochastic Processes | 1 | 2020 | 70 | 0.040 |
Why?
|
| T-Box Domain Proteins | 1 | 2020 | 98 | 0.040 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2020 | 63 | 0.040 |
Why?
|
| Aspartate Aminotransferases | 1 | 2020 | 90 | 0.040 |
Why?
|
| Oleic Acids | 1 | 2019 | 11 | 0.040 |
Why?
|
| Mobility Limitation | 1 | 2020 | 61 | 0.040 |
Why?
|
| Fractals | 1 | 2019 | 8 | 0.040 |
Why?
|
| Cryosurgery | 1 | 2020 | 59 | 0.040 |
Why?
|
| Radionuclide Imaging | 1 | 2019 | 118 | 0.040 |
Why?
|
| Models, Animal | 1 | 2021 | 384 | 0.040 |
Why?
|
| Receptors, Complement 3d | 1 | 2020 | 141 | 0.040 |
Why?
|
| Prostheses and Implants | 1 | 2021 | 143 | 0.040 |
Why?
|
| Autoantigens | 1 | 2022 | 430 | 0.040 |
Why?
|
| Staphylococcal Infections | 1 | 2024 | 400 | 0.040 |
Why?
|
| Tertiary Lymphoid Structures | 1 | 2019 | 6 | 0.040 |
Why?
|
| Animal Feed | 1 | 2019 | 53 | 0.040 |
Why?
|
| Chemokine CXCL13 | 1 | 2019 | 8 | 0.040 |
Why?
|
| Amino Acid Sequence | 3 | 2013 | 2139 | 0.040 |
Why?
|
| Alkaline Phosphatase | 1 | 2020 | 148 | 0.040 |
Why?
|
| Antidepressive Agents | 1 | 2021 | 236 | 0.040 |
Why?
|
| Alanine Transaminase | 1 | 2020 | 157 | 0.040 |
Why?
|
| Pulmonary Medicine | 1 | 2020 | 85 | 0.040 |
Why?
|
| Pulmonary Surfactant-Associated Protein A | 1 | 2019 | 35 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2022 | 7604 | 0.040 |
Why?
|
| Receptors, Immunologic | 1 | 2020 | 216 | 0.040 |
Why?
|
| Pulmonary Surfactant-Associated Protein C | 1 | 2019 | 45 | 0.040 |
Why?
|
| GTPase-Activating Proteins | 1 | 2019 | 83 | 0.040 |
Why?
|
| Systole | 1 | 2019 | 189 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 1991 | 2253 | 0.040 |
Why?
|
| Healthy Volunteers | 1 | 2019 | 199 | 0.040 |
Why?
|
| RNA, Bacterial | 1 | 2020 | 190 | 0.040 |
Why?
|
| Electric Countershock | 1 | 2019 | 107 | 0.040 |
Why?
|
| Exoribonucleases | 1 | 2019 | 49 | 0.040 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2013 | 249 | 0.040 |
Why?
|
| Endosonography | 1 | 2020 | 156 | 0.040 |
Why?
|
| Mass Spectrometry | 1 | 2022 | 739 | 0.040 |
Why?
|
| Autoimmunity | 1 | 2004 | 908 | 0.040 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2019 | 137 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2021 | 452 | 0.040 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2022 | 580 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2022 | 956 | 0.040 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2019 | 99 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2023 | 561 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2020 | 280 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 1999 | 329 | 0.040 |
Why?
|
| Reoperation | 1 | 2021 | 573 | 0.040 |
Why?
|
| Interleukin-2 | 2 | 2013 | 455 | 0.040 |
Why?
|
| Benchmarking | 1 | 2019 | 186 | 0.040 |
Why?
|
| Creatinine | 1 | 2020 | 499 | 0.040 |
Why?
|
| Bile Acids and Salts | 1 | 2019 | 200 | 0.040 |
Why?
|
| Caenorhabditis elegans | 1 | 2021 | 306 | 0.040 |
Why?
|
| Endothelial Cells | 1 | 2023 | 785 | 0.040 |
Why?
|
| Receptor, Parathyroid Hormone, Type 1 | 1 | 2017 | 3 | 0.040 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2019 | 185 | 0.040 |
Why?
|
| DNA Helicases | 1 | 2019 | 145 | 0.040 |
Why?
|
| Janus Kinase 1 | 1 | 2017 | 24 | 0.040 |
Why?
|
| Telomere-Binding Proteins | 1 | 2019 | 122 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2002 | 1050 | 0.030 |
Why?
|
| New York City | 1 | 2017 | 85 | 0.030 |
Why?
|
| High Mobility Group Proteins | 1 | 2017 | 44 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2004 | 2057 | 0.030 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2017 | 45 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 2020 | 491 | 0.030 |
Why?
|
| RNA Splicing Factors | 1 | 2017 | 53 | 0.030 |
Why?
|
| Forecasting | 1 | 2019 | 389 | 0.030 |
Why?
|
| Chromosome Mapping | 2 | 2004 | 523 | 0.030 |
Why?
|
| Child | 4 | 2022 | 21935 | 0.030 |
Why?
|
| Epigenomics | 1 | 2017 | 115 | 0.030 |
Why?
|
| Echocardiography | 1 | 2020 | 642 | 0.030 |
Why?
|
| Mucin-5B | 1 | 2019 | 224 | 0.030 |
Why?
|
| Cross-Sectional Studies | 2 | 2011 | 5472 | 0.030 |
Why?
|
| Telomerase | 1 | 2019 | 250 | 0.030 |
Why?
|
| Consensus | 1 | 2020 | 683 | 0.030 |
Why?
|
| Base Sequence | 2 | 2014 | 2181 | 0.030 |
Why?
|
| Vitamin D | 1 | 2020 | 397 | 0.030 |
Why?
|
| Sleep Wake Disorders | 1 | 2020 | 286 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2021 | 660 | 0.030 |
Why?
|
| Poverty | 1 | 2020 | 521 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2019 | 812 | 0.030 |
Why?
|
| Stroke Volume | 1 | 2019 | 612 | 0.030 |
Why?
|
| Defibrillators, Implantable | 1 | 2019 | 315 | 0.030 |
Why?
|
| Brain Diseases | 1 | 1997 | 141 | 0.030 |
Why?
|
| Chronic Pain | 1 | 2020 | 262 | 0.030 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2020 | 293 | 0.030 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2017 | 220 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 1289 | 0.030 |
Why?
|
| Hospitals | 1 | 2020 | 691 | 0.030 |
Why?
|
| Quantitative Trait Loci | 1 | 2017 | 380 | 0.030 |
Why?
|
| Mitochondrial Proteins | 1 | 2017 | 257 | 0.030 |
Why?
|
| Comorbidity | 1 | 2020 | 1622 | 0.030 |
Why?
|
| Atherosclerosis | 1 | 2019 | 415 | 0.030 |
Why?
|
| Alcohol Drinking | 1 | 2021 | 828 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2022 | 1496 | 0.030 |
Why?
|
| Molecular Sequence Data | 2 | 2014 | 2900 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2017 | 430 | 0.030 |
Why?
|
| Software | 1 | 2019 | 665 | 0.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2017 | 455 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 2017 | 427 | 0.030 |
Why?
|
| Protective Devices | 1 | 2014 | 31 | 0.030 |
Why?
|
| Calcium | 1 | 2020 | 1199 | 0.030 |
Why?
|
| Health Personnel | 1 | 2020 | 710 | 0.030 |
Why?
|
| Heme Oxygenase-1 | 1 | 2014 | 64 | 0.030 |
Why?
|
| United States Occupational Safety and Health Administration | 1 | 2013 | 7 | 0.030 |
Why?
|
| B7-1 Antigen | 1 | 2013 | 58 | 0.030 |
Why?
|
| Hematologic Tests | 1 | 2013 | 22 | 0.030 |
Why?
|
| Cardiac Imaging Techniques | 1 | 2013 | 21 | 0.030 |
Why?
|
| Lymphokines | 1 | 2013 | 131 | 0.030 |
Why?
|
| Gene Transfer, Horizontal | 1 | 2013 | 34 | 0.030 |
Why?
|
| Peptide Library | 1 | 2013 | 92 | 0.030 |
Why?
|
| Drug Resistance, Microbial | 1 | 2013 | 71 | 0.020 |
Why?
|
| Etanercept | 1 | 2012 | 57 | 0.020 |
Why?
|
| Immunity | 1 | 2013 | 143 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2024 | 2654 | 0.020 |
Why?
|
| Infusions, Parenteral | 1 | 2012 | 40 | 0.020 |
Why?
|
| Interdisciplinary Communication | 1 | 2013 | 191 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2016 | 1060 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2019 | 3015 | 0.020 |
Why?
|
| Colony Count, Microbial | 1 | 2012 | 120 | 0.020 |
Why?
|
| Microscopy, Immunoelectron | 1 | 1991 | 46 | 0.020 |
Why?
|
| Hyperplasia | 1 | 2012 | 175 | 0.020 |
Why?
|
| Phagocytes | 2 | 2004 | 101 | 0.020 |
Why?
|
| Immunotoxins | 1 | 1991 | 55 | 0.020 |
Why?
|
| Mammals | 1 | 2013 | 283 | 0.020 |
Why?
|
| Self Report | 1 | 2015 | 827 | 0.020 |
Why?
|
| Program Development | 1 | 2013 | 364 | 0.020 |
Why?
|
| Needs Assessment | 1 | 2013 | 376 | 0.020 |
Why?
|
| Keratinocytes | 1 | 2012 | 249 | 0.020 |
Why?
|
| Ontario | 1 | 2011 | 148 | 0.020 |
Why?
|
| Hypertension | 1 | 2020 | 1295 | 0.020 |
Why?
|
| Depression | 1 | 2020 | 1397 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2019 | 2389 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2011 | 390 | 0.020 |
Why?
|
| Gold | 1 | 1991 | 118 | 0.020 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2011 | 144 | 0.020 |
Why?
|
| Educational Measurement | 1 | 2013 | 289 | 0.020 |
Why?
|
| Plasmids | 1 | 1991 | 363 | 0.020 |
Why?
|
| Japan | 1 | 2010 | 115 | 0.020 |
Why?
|
| Regeneration | 1 | 2012 | 197 | 0.020 |
Why?
|
| Risk | 2 | 2004 | 912 | 0.020 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2010 | 81 | 0.020 |
Why?
|
| Binding Sites | 1 | 2013 | 1303 | 0.020 |
Why?
|
| CD3 Complex | 1 | 2010 | 106 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2012 | 657 | 0.020 |
Why?
|
| United Kingdom | 1 | 2010 | 318 | 0.020 |
Why?
|
| Antigen-Presenting Cells | 1 | 2009 | 156 | 0.020 |
Why?
|
| Transfection | 1 | 1991 | 945 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2010 | 191 | 0.020 |
Why?
|
| Receptor, ErbB-2 | 1 | 1991 | 341 | 0.020 |
Why?
|
| Blood Proteins | 1 | 2011 | 252 | 0.020 |
Why?
|
| 4-1BB Ligand | 1 | 2008 | 7 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2013 | 898 | 0.020 |
Why?
|
| Demography | 1 | 2009 | 291 | 0.020 |
Why?
|
| Hypertension, Pulmonary | 1 | 2020 | 1910 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2011 | 1316 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2009 | 318 | 0.020 |
Why?
|
| Peptides | 1 | 2013 | 985 | 0.020 |
Why?
|
| Codon | 1 | 2007 | 89 | 0.020 |
Why?
|
| Adjuvants, Immunologic | 1 | 2008 | 226 | 0.020 |
Why?
|
| Obesity | 1 | 2020 | 2992 | 0.020 |
Why?
|
| Fibrosis | 1 | 2009 | 552 | 0.020 |
Why?
|
| Fibroblasts | 1 | 1991 | 996 | 0.020 |
Why?
|
| Cell Survival | 1 | 2009 | 1120 | 0.020 |
Why?
|
| Transcription Factor AP-1 | 1 | 2006 | 92 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2006 | 140 | 0.020 |
Why?
|
| Catalytic Domain | 1 | 2006 | 207 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2005 | 272 | 0.010 |
Why?
|
| Caspase 8 | 1 | 2005 | 48 | 0.010 |
Why?
|
| RNA Precursors | 1 | 2006 | 154 | 0.010 |
Why?
|
| Free Radical Scavengers | 1 | 2005 | 88 | 0.010 |
Why?
|
| Lymphocyte Count | 1 | 2005 | 148 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2005 | 375 | 0.010 |
Why?
|
| Nuclear Family | 1 | 2004 | 54 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 2004 | 47 | 0.010 |
Why?
|
| Radioisotopes | 1 | 2004 | 31 | 0.010 |
Why?
|
| Metalloporphyrins | 1 | 2005 | 103 | 0.010 |
Why?
|
| Caspases | 1 | 2005 | 247 | 0.010 |
Why?
|
| Species Specificity | 1 | 2005 | 585 | 0.010 |
Why?
|
| Infant | 1 | 2017 | 9465 | 0.010 |
Why?
|
| Reference Values | 1 | 2004 | 816 | 0.010 |
Why?
|
| Kinetics | 1 | 2006 | 1670 | 0.010 |
Why?
|
| Rats | 1 | 1991 | 5647 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2017 | 11074 | 0.010 |
Why?
|
| Genes, T-Cell Receptor beta | 1 | 2002 | 22 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2002 | 124 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2002 | 189 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2006 | 712 | 0.010 |
Why?
|
| Incidence | 1 | 2008 | 2804 | 0.010 |
Why?
|
| Utah | 1 | 2001 | 69 | 0.010 |
Why?
|
| Oximetry | 1 | 2001 | 96 | 0.010 |
Why?
|
| Tetanus Toxoid | 1 | 2000 | 35 | 0.010 |
Why?
|
| Bromodeoxyuridine | 1 | 2000 | 79 | 0.010 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2000 | 98 | 0.010 |
Why?
|
| Lectins, C-Type | 1 | 2000 | 67 | 0.010 |
Why?
|
| Volatilization | 1 | 2000 | 56 | 0.010 |
Why?
|
| Scattering, Radiation | 1 | 2000 | 101 | 0.010 |
Why?
|
| HLA-DP alpha-Chains | 1 | 1999 | 4 | 0.010 |
Why?
|
| Genetic Carrier Screening | 1 | 1999 | 28 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2004 | 718 | 0.010 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2000 | 137 | 0.010 |
Why?
|
| Dimerization | 1 | 1999 | 199 | 0.010 |
Why?
|
| Acute Disease | 1 | 2002 | 1007 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2006 | 1719 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 2000 | 321 | 0.010 |
Why?
|
| Equipment Design | 1 | 2000 | 522 | 0.010 |
Why?
|
| Cell Movement | 1 | 2002 | 967 | 0.010 |
Why?
|
| Skin | 1 | 2002 | 752 | 0.010 |
Why?
|
| Light | 1 | 2000 | 381 | 0.010 |
Why?
|